Glioma CpG island methylator phenotype (G-CIMP): Biological and clinical implications

Neuro-Oncology

Volumn 20, Issue 5, 2018, Pages 608-620

  Malta, Tathiane M ^a,b   De Souza, Camila F ^a,b   Sabedot, Thais S ^a,b   Silva, Tiago C ^b   Mosella, Maritza S ^b   Kalkanis, Steven N ^a   Snyder, James ^a   Castro, Ana Valeria B ^a   Noushmehr, Houtan ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CpG island methylator phenotype (CIMP); DNA methylation; G CIMP (glioma CIMP); glioma progression; IDH mutation; molecular subtypes

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYL CPG BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; GENE; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GLIOMA; HUMAN; IDH GENE; METHYL-CPG-BINDING DOMAIN; MGMT GENE; PHENOTYPE; PREDICTIVE VALUE; PROMOTER REGION; SURVIVAL ANALYSIS; GENETICS; HUMAN GENOME; MUTATION; PATHOLOGY;

CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; GENOME, HUMAN; GLIOMA; HUMANS; MUTATION; PHENOTYPE;

EID: 85045140633     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox183     Document Type: Article

References (100)

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classifcation of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820.
2. Masui K, Mischel PS, Reifenberger G. Molecular classifcation of glio-mas. Handb Clin Neurol. 2016;134:97-120.
3. Siegal T. Clinical relevance of prognostic and predictive molecular markers in gliomas. Adv Tech Stand Neurosurg 2016;(43):91-108.
4. Taylor JW, Chi AS, Cahill D P. Tailored therapy in diffuse gliomas: using molecular classifers to optimize clinical management. Oncology (Williston Park). 2013;27(6):504-514.
5. Gittleman H, Lim D, Kattan MW, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol 2016;19(5):669-677.
6. Hoadley KA, Yau C, Wolf DM, et al; Cancer Genome Atlas Research Network. Multiplatform analysis of 12 cancer types reveals molecular classifcation within and across tissues of origin. Cell. 2014;158(4):929-944.
7. Ceccarelli M, Barthel F P, Malta TM, et al; TCGA Research Network. Molecular profling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
8. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97(5):1276-1284.
9. Cairncross JG, Ueki K, Zlatescu MC, et al. Specifc genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479.
10. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
11. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508.
12. Brat DJ, Verhaak RG, Aldape KD, et al; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372(26):2481-2498.
13. LeBlanc VG, Marra MA. DNA methylation in adult diffuse gliomas. Brief Funct Genomics. 2016;15(6):491-500.
14. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
15. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871-1874.
16. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
17. Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12(2):116-121.
18. Noushmehr H, Weisenberger DJ, Diefes K, et al; Cancer Genome Atlas Research Network. Identifcation of a CpG island methylator phenotype that defnes a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
19. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is suffcient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.
20. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27-36.
21. Shen H, Laird PW. Interplay between the cancer genome and epig-enome. Cell. 2013;153(1):38-55.
22. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143-153.
23. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481-514.
24. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011;25(23):2436-2452.
25. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196(2):261-282.
26. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450, 000 CpG sites in the human genome. Epigenetics. 2011;6(6):692-702.
27. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science. 1998;281(5373):60-63.
28. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epi-genetic mechanisms. Nat Rev Genet. 2006;7(9):703-713.
29. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature. 2000;405(6785):486-489.
30. Liu XS, Wu H, Ji X, et al. Editing DNA methylation in the mammalian genome. Cell. 2016;167(1):233-247.e17.
31. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular repro-gramming. Trends Cell Biol. 2010;20(10):609-617.
32. Lee ST, Wiemels JL. Genome-wide CpG island methylation and inter-genic demethylation propensities vary among different tumor sites. Nucleic Acids Res. 2016;44(3):1105-1117.
33. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chroma-tin formation and gene expression in cancer. Hum Mol Genet. 2001;10(7):687-692.
34. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698-711.
35. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethyl-ome. Hum Mol Genet 2007;16(1):R50-9.
36. Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011;43(8):768-775.
37. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681-8686.
38. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest. 2014;124(1):17-23.
39. Miller BF, Sánchez-Vega F, Elnitski L. The emergence of pan-cancer CIMP and its elusive interpretation. Biomolecules 2016;6(4):pii: E45.
40. Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological sig-nifcance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014;455(1-2):35-42.
41. Witte T, Plass C, Gerhauser C. Pan-cancer patterns of DNA methylation. Genome Med. 2014;6(8):66.
42. Sánchez-Vega F, Gotea V, Margolin G, Elnitski L. Pan-cancer stratifcation of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specifc features of the CpG island methylator pheno-type. Epigenetics Chromatin. 2015;8:14.
43. Verhaak RG, Hoadley KA, Purdom E, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
44. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
45. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 defne distinct epigenetic and biological subgroups of glioblast-oma. Cancer Cell. 2012;22(4):425-437.
46. Brennan CW, Verhaak RG, McKenna A, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
47. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561-571.
48. Mur P, Rodríguez de Lope Á, Díaz-Crespo FJ, et al. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. J Neurooncol. 2015;122(3):441-450.
49. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classi-fcation of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol. 2013;15(4):469-479.
50. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515-1522.
51. Cairncross JG, Wang M, Jenkins RB, et al. Beneft from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783-790.
52. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345.
53. Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 muta-tions as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171-180.
54. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
55. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
56. Wiestler B, Claus R, Hartlieb SA, et al; Neuro-oncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013;15(8):1017-1026.
57. Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted glio-mas are mutated on IDH1 or IDH2. Neurology. 2010;74(23):1886-1890.
58. Mur P, Mollejo M, Ruano Y, et al. Codeletion of 1p and 19q determines distinct gene methylation and expression profles in IDH-mutated oligo-dendroglial tumors. Acta Neuropathol. 2013;126(2):277-289.
59. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infnium methylation BeadChip identifes two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547-560.
60. van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phe-notype is a better predictor of survival than MGMT methylation in ana-plastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011;17(22):7148-7155.
61. Wiestler B, Capper D, Hovestadt V, et al. Assessing CpG island meth-ylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol. 2014;16(12):1630-1638.
62. Wick W, Roth P, Hartmann C, et al; Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemother-apy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18(11):1529-1537.
63. Duncan CG, Barwick BG, Jin G, et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012;22(12):2339-2355.
64. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
65. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
66. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19(1):17-30.
67. Tateishi K, Wakimoto H, Iafrate AJ, et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell. 2015;28(6):773-784.
68. Chiarugi A, Dölle C, Felici R, Ziegler M. The NAD metabolome- A key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741-752.
69. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone dem-ethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
70. Dahlin AM, Wibom C, Ghasimi S, Brännström T, Andersson U, Melin B. Relation between established glioma risk variants and DNA methylation in the tumor. PLoS One. 2016;11(10):e0163067.
71. Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al; GliomaScan Consortium. Genome-wide association study of glioma subtypes iden-tifes specifc differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789-794.
72. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115(5):948-965.
73. de Souza CF, Sabedot TS, Malta TM, et al. Distinct epigenetic shift in a subset of glioma CpG island methylator phenotype (G-CIMP) during tumor recurrence. bioRxiv 156646. doi:10.1101/156646
74. Mazor T, Pankov A, Johnson BE, et al. DNA methylation and somatic mutations converge on the cell cycle and defne similar evolutionary his-tories in brain tumors. Cancer Cell. 2015;28(3):307-317.
75. Bai H, Harmanci AS, Erson-Omay EZ, et al. Integrated genomic char-acterization of IDH1-mutant glioma malignant progression. Nat Genet. 2016;48(1):59-66.
76. Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110-114.
77. Suvà ML, Rheinbay E, Gillespie SM, et al. Reconstructing and repro-gramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014;157(3):580-594.
78. Sarkar A, Hochedlinger K. The Sox family of transcription factors: ver-satile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12(1):15-30.
79. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron. 2003;39(5):749-765.
80. Berezovsky AD, Poisson LM, Cherba D, et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia. 2014;16(3):193-206, 206.e19.
81. Jones PA, Issa J P, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630-641.
82. Chen R, Cohen AL, Colman H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options Oncol. 2016;17(8):42.
83. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256-266.
84. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas-implications for clas-sifcation and therapy. Nat Rev Clin Oncol. 2017;14(7):434-452.
85. Maio M, Covre A, Fratta E, et al. Molecular pathways: at the cross-roads of cancer epigenetics and immunotherapy. Clin Cancer Res. 2015;21(18):4040-4047.
86. Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127.
87. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics. 2006;1(1):7-13.
88. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76(7):1683-1689.
89. Roulois D, Yau HL, De Carvalho DD. Pharmacological DNA demethylation: implications for cancer immunotherapy. Oncoimmunology. 2016;5(3):e1090077.
90. Licht JD. DNA methylation inhibitors in cancer therapy: the immunity dimension. Cell. 2015;162(5):938-939.
91. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013;4(11):2067-2079.
92. Turcan S, Fabius AW, Borodovsky A, et al. Effcient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget. 2013;4(10):1729-1736.
93. Feng J, Yan PF, Zhao HY, Zhang FC, Zhao WH, Feng M. Inhibitor of nico-tinamide phosphoribosyltransferase sensitizes glioblastoma cells to temozolomide via activating ROS/JNK signaling pathway. Biomed Res Int. 2016;2016:1450843.
94. Obata Y, Furusawa Y, Hase K. Epigenetic modifications of the immune system in health and disease. Immunol Cell Biol. 2015;93(3):226-232.
95. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324-327.
96. Dimitrov L, Hong CS, Yang C, Zhuang Z, Heiss JD. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci. 2015;12(3):201-213.
97. Tivnan A, Heilinger T, Lavelle EC, Prehn JH. Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol. 2017;131(1):1-9.
98. Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19(11):1460-1468.
99. Park J, Thomas S, Munster PN. Epigenetic modulation with histone dea-cetylase inhibitors in combination with immunotherapy. Epigenomics. 2015;7(4):641-652.
100. Sahebjam S, McNamara MG, Mason W P. Emerging biomarkers in ana-plastic oligodendroglioma: implications for clinical investigation and patient management. CNS Oncol. 2013;2(4):351-358.